| Zacks Company Profile for Synlogic, Inc. (SYBX : NSDQ) |
|
|
| |
| • Company Description |
| Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company's pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts.
Number of Employees: 1 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $1.20 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 6,018 shares |
| Shares Outstanding: 11.70 (millions) |
| Market Capitalization: $14.03 (millions) |
| Beta: 0.55 |
| 52 Week High: $1.88 |
| 52 Week Low: $0.90 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-2.44% |
-6.46% |
| 12 Week |
16.50% |
2.09% |
| Year To Date |
-14.29% |
-19.05% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Mary Beth Dooley - Principal Executive Officer and Principal Financia
Peter Barrett - Chairman
James Flynn - Director
Edward Mathers - Director
Richard P. Shea - Director
|
|
Peer Information
Synlogic, Inc. (CORR.)
Synlogic, Inc. (RSPI)
Synlogic, Inc. (CGXP)
Synlogic, Inc. (BGEN)
Synlogic, Inc. (GTBP)
Synlogic, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87166L209
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/24
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 11.70
Most Recent Split Date: 9.00 (0.07:1)
Beta: 0.55
Market Capitalization: $14.03 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.11 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.47 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
